Iron Repletion for Patients with Heart Failure and Kidney Dysfunction
- 9 August 2023
- journal article
- editorial
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (9) , 1111-1112
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney FunctionClinical Journal of the American Society of Nephrology, 2023
- Daprodustat for the Treatment of Anemia in Patients Not Undergoing DialysisNew England Journal of Medicine, 2021
- Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trialThe Lancet, 2020
- Intravenous Iron in Patients Undergoing Maintenance HemodialysisNew England Journal of Medicine, 2019
- Effects of Ferric Carboxymaltose on Hospitalisations and Mortality Rates in Iron-Deficient Heart Failure Patients: An Individual Patient data Meta-AnalysisEuropean Journal of Heart Failure, 2017
- FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemiaNephrology Dialysis Transplantation, 2014
- The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit TrialKidney International, 2012
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyNew England Journal of Medicine, 2009
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2009
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998